TOLREMO therapeutics’ Post

Top venture pick of the day: Hub71 based BioSapien: a local cancer treatment that can be attached to any tissue, with the drug injected directly into the tumor, resulting in minimal treatment side effects. Clinical protocol has been approved, clinical trials are on fast track, and manufacturing is starting. Backed by Meet the Drapers, Certara, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, UC San Diego, Vanderbilt University, SOSV, Hikma Pharmaceuticals, MicroVentures, National Science Foundation (NSF), Techstars. Khatija A. Sonia Ramamoorthy Joseph Borrello Martin Krusin Janet S Lee, PhD Agnes Westelinck David Jacobson-Kram Julie Bullock Abhishek Gupta Jedd Wolchok

Exciting news! Our Business Development team is in Charlotte, North Carolina this week end to attend the AACR special conference on bladder cancer. If you're attending as well, be sure to stop by our booth to learn about how our cutting-edge #MIBC and #NMIBC models for preclinical oncology drug development. See you there! Discover more https://hubs.ly/Q02xFVXb0 #AACR2024 #BladderCancer #OncologyResearch #PreclinicalDrugDevelopment.

Pioneering Breakthroughs Together: A recent dialogue between Dr. Krystle Karoscik , COO of InnovoTEX Inc. and Merom Klein from Courage Growth Partners unveils opportunities in biotech. Learn about InnovoTEX's strategic approach to leveraging biotech advancements, setting the stage for groundbreaking progress in ovarian cancer treatments. This discussion exemplifies how our collective expertise and collaborative efforts lead to innovative solutions that change lives. #HealthcareInnovation #CollaborativeExcellence #KeiretsuForum

'The Biologics Workstream has the power to actually realize the implementation of the innovative approaches within the full infrastructure.' Debby Vermeer-Kruijsen, Ph.D. and Jeanette Leusen (UMC Utrecht) delve into the world of Biologics and explore how the Biologics workstream is innovating cancer therapy within the Oncode Accelerator Program. Read our interview with Debby and Jeanette on our website. #drugdevelopment #preclinicalresearch #cancerresearch https://lnkd.in/esFT2EY2

Immunotherapies have transformed cancer treatment, but considerable challenges remain. At Mural Oncology, we are using our advanced protein engineering capabilities to broaden the potential and reach of cytokine-based immunotherapies for people with cancer. Our lead candidate, nemvaleukin, is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose native IL-2 while mitigating the cytokine’s hallmark toxicities. It is currently in two potentially registrational trials reading out next year. Discover our pipeline and learn about the clinical trials evaluating nemvaleukin: https://bit.ly/49hUu3c #biotechnology #oncology #drugdevelopment

🌟A recent study using our #ResearchChemicals identified the enzyme DECR2 as a promising therapeutic target in treating preclinical models of castration-resistant #ProstateCancer. Read the full study in the British Journal of Cancer: https://okt.to/BlUTnk 💡Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/m4QyZ1 #oncology #oncologyresearch #ProductCitation

Pioneering Breakthroughs Together: A recent dialogue between Dr. Krystle Karoscik , COO of InnovoTEX Inc. and Merom Klein from Courage Growth Partners unveils opportunities in biotech. Learn about InnovoTEX's strategic approach to leveraging biotech advancements, setting the stage for groundbreaking progress in ovarian cancer treatments. This discussion exemplifies how our collective expertise and collaborative efforts lead to innovative solutions that change lives. #HealthcareInnovation #CollaborativeExcellence #KeiretsuForum

Designing surface-bioengineered extracellular vesicles to target lung cancer cells: in their latest work, Ireneusz P. Grudzinski and Anna M. Nowicka at University of Warsaw and collaborators bioengineered extracellular vesicles from lung cancer cells, decorating them with the heptapeptide PTHTRWA, the most effective peptide for binding to lung cancer cells. https://lnkd.in/eHukjPtd Preclinical safety assays revealed no cytotoxic or genotoxic effects of these novel bioconstructs, though impedance-based studies indicated some transient impacts on endothelial barrier integrity. An article co-authored by Agata Kowalczyk, Damian Dziubak, Artur Kasprzak, Kamil Sobczak, Monika Rużycka, Magdalena Bamburowicz-Klimkowska, Slawomir Sek, Ivan Rios Mondragon, Teresa Żołek, Elise Rundén Pran, Sergey Shaposhnikov, Mihaela Roxana C. and Maria Dusinska #extracellularvesicles #exosomes #bioengineering #lungcancer #clickchemistry #Vesiculab

A breathtaking leap in T-cell therapy innovation! 💡🧬✨ Adaptimmune's recent licensing agreement with Galapagos marks a transformative moment for cancer treatment. The deal involves uza-cel, a groundbreaking therapy for ovarian cancer, now expanding into head and neck cancers—potentially transforming outcomes for patients with solid tumors. The robust collaboration involves a substantial financial commitment from Galapagos: 💷 $100 million upfront, additional milestones totaling up to $665 million, and future royalties. This lifeline not only empowers Adaptimmune's continued innovation but also propels their afami-cel towards launch for treating synovial sarcoma. Investors are rallying, with shares surging by 21% pre-market! 📈 Such a strategic alliance reinforces the power of partnership in navigating financial challenges and maximising therapeutic impact. Embracing Galapagos' decentralized manufacturing could revolutionize treatment efficacy and accessibility. As we await FDA decisions and further trial results, this partnership kindles hope for those fighting cancer. ✊🎗️ #Innovation #CancerTreatment #BiotechIndustry

Delve into the molecular intricacies of cancer with DRUG-seq, an affordable and efficient RNA-seq application that is changing the landscape of oncology drug discovery. This state-of-the-art technology drives innovation in investigating mechanisms of drug action, profiling drug responses, discovering biomarkers, and untangling tumor heterogeneity. Contact us to find out how you can use Champions' new DRUG-seq platform to generate fast insights in drug discovery. https://hubs.li/Q02pvCkq0 #DRUGseq #OncologyResearch #CancerResearch #RNAseq #MechanismOfAction #DrugResponse #DrugResistance #BiomarkerDiscovery #TumorHeterogeneity #Oncology #Cancer #PrecisionMedicine #DrugDiscovery #endpointspotlight